| 1. KEYTRUDA is a registered trademark of Merck & Co., Inc. KYMRIAH is a registered trademark of Novartis Pharmaceuticals Corporation.
Grab Sources Here: CTXR Presentation. -----
And as I mentioned above, there are 4 potential catalysts we're focused on for (Nasdaq: CTXR) at the moment. Check them out:
#1. CTXR Potential Catalyst - A Low Float Could Create A Volatility Storm Quickly.
According to info from the Yahoo Finance website, CTXR has a relatively low float.
In fact, the website reports this profile to have approximately 16.26Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If positive company news appears in the midway part of 2025, could it provide a breakout spark? -----
#2. CTXR Potential Catalyst - A Distribution Expansion Agreement Could Prove Fruitful As Commercialization Nears.
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™
CRANFORD, N.J., July 15, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the execution of a distribution services agreement with Cencora (formerly AmerisourceBergen), a global pharmaceutical services company. This agreement marks another significant step forward in the Company's commercial launch strategy for LYMPHIR (denileukin diftitox-cxdl), its FDA-approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
This new agreement expands Citius Oncology's commercial distribution network, providing additional access and product availability upon launch. The agreement with Cencora, a leader in specialty pharmaceutical distribution and services, builds on a previously announced distribution services agreement to support long-term scalability and market reach of LYMPHIR.
"As we move closer to the U.S. market introduction of LYMPHIR, we remain focused on disciplined execution across all key commercial readiness activities," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals. "Our agreement with Cencora adds further depth to our distribution strategy and strengthens our ability to deliver LYMPHIR to treatment centers across the country. These foundational partnerships demonstrate our ongoing commitment to building a launch platform that supports near-term revenue and long-term shareholder value."
Under the terms of the agreement, Cencora will serve as a wholesale distributor for LYMPHIR, providing specialty distribution services to facilitate product availability across its distribution network.
Read the full article here. -----
#3. CTXR Potential Catalyst - Final Preparations Are In Process For A U.S. LYMPHIR Launch In 2H 2025.
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
CRANFORD, N.J., June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that preparations for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), are nearing completion. The Company believes it is now operationally positioned to transition from a development-stage enterprise to a fully integrated commercial organization, with all major launch-enabling activities underway. Final preparations are in process for a U.S. launch of LYMPHIR in the second half of 2025.
"We've made steady and meaningful progress toward commercialization over the past several months," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma. "With our supply chain secured, market access supported, and no anticipated impediments to reimbursement, we are encouraged by the momentum we've built. These efforts are pivotal as we transition into a commercial-stage company and believe the planned 2025 launch of LYMPHIR has the potential to be an important inflection point for both the company and the CTCL community," added Mazur.
...
Read the full article here. -----
#4. CTXR Potential Catalyst - A Distribution Services Agreement With Cardinal Health Marks A Key Step Forward Towards Commercialization.
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health
Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma
CRANFORD, N.J., June 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has entered into a distribution services agreement with Cardinal Health (NYSE: CAH), a leading provider of pharmaceutical and specialty pharmaceutical distribution services in the United States.
This agreement is designed to help provide access to LYMPHIR™ (denileukin diftitox-cxdl), an innovative immunotherapy FDA-approved for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), in support of its anticipated U.S. commercial launch.
"This agreement marks a key step forward in our launch readiness efforts," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals. "Cardinal Health's proven distribution capabilities will help ensure LYMPHIR reaches healthcare providers and patients efficiently and reliably, as we work to build a robust commercial distribution network."
Under the agreement, Cardinal Health will serve as an authorized distributor of record for Citius Oncology providing specialty pharmaceutical distribution services.
Read the full article here. -----
#5 CTXR Potential Catalyst - A Unique Permanent J-Code Marks A Critical Milestone In Supporting Patient Access To LYMPHIR.
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
CRANFORD, N.J., Feb. 6, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today announced that LYMPHIR™ (denileukin diftitox-cxdl) has been assigned a unique, permanent Hea.lthcare Common Procedure Coding System (HCPCS) J-code (J9161) by the Centers for Medicare & Medicaid Services (CMS).
...
"The establishment of a permanent J-code marks a critical milestone in supporting patient access to LYMPHIR, providing coding clarity for physicians and facilities who administer LYMPHIR, and facilitating reimbursement. This achievement is a key step in ensuring that LYMPHIR is accessible to patients with commercial and government insurance (VA, DoD, Medicare) coverage," stated Leonard Mazur, Chairman and CEO of Citius Pharma and Citius Oncology.
J-codes are unique identifiers utilized by U.S. government and commercial payers, as well as physicians and their office staff, to streamline the billing and reimbursement process for infused therapies and certain other treatments.
Read the full article here. -----
(Nasdaq: CTXR) Recap - 5 Potential Catalysts Lead The Way!
#1. A Low Float Could Create A Volatility Storm Quickly.
#2. A Distribution Expansion Agreement Could Prove Fruitful As Commercialization Nears.
#3. Final Preparations Are In Process For A U.S. LYMPHIR Launch In 2H 2025.
#4. A Distribution Services Agreement With Cardinal Health Marks A Key Step Forward Towards Commercialization.
#5. A Unique Permanent J-Code Marks A Critical Milestone In Supporting Patient Access To LYMPHIR. -----
Coverage is officially kicked off on Citius Pharmaceuticals, Inc. (Nasdaq: CTXR).
I'll be back to you with updates as soon as they are available. Talk soon.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 08/22/2025 and ending on 08/22/2025 to publicly disseminate information about (CTXR:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid eighty seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (CTXR:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/ctxr-xi2xe/#details | 
0 التعليقات:
إرسال تعليق